Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Reducing the severity of respiratory disease
The effect of immune-modulators in equine medicine

An Animal Health Trust (AHT) review has found that immune-modulators can reduce the severity of some respiratory diseases in horses.

The review, which has been published in Veterinary Immunology and Immunopathology, was conducted by Romain Paillot, who works at AHT.

His work involved examining scientific literature and reports on the use of immune-modulators in equine medicine, in particular, for the prevention or treatment of respiratory disease.

The two immune-modulators studied were Parapoxvirus ovis (iPPVO) and Propionbacterium acnes (P.acnes), which are both used to improve immune defences and prevent or treat infectious diseases in horses.

Dr Paillot found that young horses treated with iPPVO and co-mingled with experimentally infected EHV-1 horses showed a reduction in disease severity by 40 per cent.

Meanwhile, those treated with iPPVO and co-mingled with horses experimentally infected with EHV-4 showed a 61 per cent reduction in disease severity.

For horses treated with P.acnes, Dr Paillot found that the frequency of recovery for horses that had shown clinical signs of respiratory disease were "significantly increased".

He said: "Non-specific immune-modulators such as iPPVO or P.acnes may not provide protection against direct infection or transmission of respiratory pathogens, but they seem to contribute to the reduction of the disease severity.

"This subsequently reduces the frequency of complications and improves the rate of recovery."

Click here to read the review.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.